Companies › H. Lundbeck
6 active drug programs in 13 registered trials: 5 Phase 3, 5 Phase 1, 3 Phase 2; Neurology, Other, Genitourinary, Metabolic and endocrine; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Eptinezumab Calcitonin gene-related peptide inhibitor | CALCA, CALCB | Phase 3 | Chronic Migraine in Children; Episodic Migraine; Migraine; Post Traumatic Headache | Mar 2027 |
| Amlenetug (Lu AF82422) | – | Phase 3 | Multiple System Atrophy | Feb 2028 |
| Lu AF28996 | – | Phase 2 | Parkinson's Disease; Parkinson Disease | May 2027 |
| Lu AG13909 11β-hydroxylase inhibitor | CYP11B1 | Phase 2 | Cushing's Disease; Congenital Adrenal Hyperplasia | Aug 2027 |
| Lu AH69593 | – | Phase 1 | Healthy Participants; Narcolepsy | Nov 2026 |
| Lu AG22515 Unclear - no mechanism stated for this investigational compound | – | Phase 1 | Thyroid Eye Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06557850 | Lu AG22515 | Phase 1 | Thyroid Eye Disease | Ophthalmology | Mar 2026 |
| NCT07775261 | Lu AH69593 | Phase 1 | Healthy Participants | Other | Nov 2026 |
| NCT07613710 | Lu AH69593 | Phase 1 | Narcolepsy | Neurology | Feb 2027 |
| NCT04965675 | Eptinezumab | Phase 3 | Chronic Migraine in Children | Neurology | Mar 2027 |
| NCT07513441 | Lu AF28996 | Phase 1 | Parkinson Disease | Neurology | May 2027 |
| NCT07191145 | Eptinezumab | Phase 3 | Post Traumatic Headache | Neurology | Jun 2027 |
| NCT05897320 | Eptinezumab | Phase 3 | Episodic Migraine | Neurology | Jul 2027 |
| NCT06471829 | Lu AG13909 | Phase 2 | Cushing's Disease | Metabolic and endocrine | Aug 2027 |
| NCT05669950 | Lu AG13909 | Phase 1 | Congenital Adrenal Hyperplasia | Genitourinary | Dec 2027 |
| NCT06706622 | Amlenetug (Lu AF82422) | Phase 3 | Multiple System Atrophy | Neurology | Feb 2028 |
| NCT05104476 | Amlenetug (Lu AF82422) | Phase 2 | Multiple System Atrophy | Neurology | Mar 2028 |
| NCT05164172 | Eptinezumab | Phase 3 | Migraine | Neurology | Apr 2028 |
| NCT07514858 | Lu AF28996 | Phase 2 | Parkinson's Disease | Neurology | Oct 2028 |
Centessa Pharmaceuticals (UK) Actinogen Medical Beijing Suncadia Pharmaceuticals UCB Biopharma SRL Praxis Precision Medicines
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.